ClinConnect ClinConnect Logo
Search / Trial NCT05681975

Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms

Launched by UNIVERSIDAD POLITECNICA DE MADRID · Jan 3, 2023

Trial Information

Current as of June 28, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how certain antibodies in the body, specifically Immunoglobulin G4 (IgG4) and Immunoglobulin E (IgE), relate to symptoms that people experience when they have adverse reactions to foods. The researchers want to understand the levels of these antibodies in individuals who have symptoms linked to food allergies or other food-related reactions.

If you are an adult over 18 years old and have experienced symptoms related to these food reactions, you may be eligible to participate in this study. However, if you are currently undergoing antibiotic treatment, you won't be able to join. Participants in the trial will help researchers gather important information that could improve our understanding of food allergies and related conditions. The study is currently looking for volunteers, so if you or someone you know fits the criteria, it could be a valuable opportunity to contribute to this important research.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults (\>18 years of age)
  • To present symptoms related to adverse reactions to foodstuffs (ARFS)
  • Exclusion Criteria:
  • Antibiotic treatment

About Universidad Politecnica De Madrid

The Universidad Politécnica de Madrid (UPM) is a leading institution in engineering and technology education, renowned for its commitment to innovation and research excellence. As a clinical trial sponsor, UPM leverages its interdisciplinary expertise to advance medical research and develop novel therapeutic solutions. The university fosters collaborations with healthcare professionals, industry partners, and research organizations to conduct rigorous clinical studies that aim to improve patient outcomes and contribute to the scientific community. With a strong emphasis on ethical practices and regulatory compliance, UPM is dedicated to enhancing the landscape of clinical research through its robust academic framework and cutting-edge facilities.

Locations

Madrid, , Spain

Patients applied

0 patients applied

Trial Officials

Lisset Pantoja-Arévalo, MSc

Principal Investigator

Universidad Politecnica de Madrid

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials